65 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
BPMC Blueprint Medicines Corporation $68.7 $3.02B Buy
Article Searches
Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today https://www.fool.com/investing/2019/01/07/why-array-biopharma-deciphera-pharmaceuticals-and.aspx?source=iedfolrf0000001 Jan 07, 2019 - Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
Blueprint Medicines' (BPMC) CEO Jeff Albers on Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4215890-blueprint-medicines-bpmc-ceo-jeff-albers-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare Oct 30, 2018 -
Blueprint Medicines 2018 Q3 - Results - Earnings Call Slides https://seekingalpha.com/article/4215758-blueprint-medicines-2018-q3-results-earnings-call-slides?source=feed_sector_healthcare Oct 30, 2018 - The following slide deck was published by Blueprint Medicines in conjunction with their 2018 Q3 earnings call.
Loxo Oncology And Blueprint Medicines Wrap Up Round 2 In RET Showdown https://seekingalpha.com/article/4213787-loxo-oncology-blueprint-medicines-wrap-round-2-ret-showdown?source=feed_sector_healthcare Oct 24, 2018 - Loxo Oncology (LOXO) and Blueprint Medicines (BPMC) both recently published updated results for their small molecule kinase inhibitors targeting RET altered thyroid cancer. Both companies reported inc
Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For http://www.zacks.com/stock/news/330186/blueprint-medicines-bpmc-q3-earnings-preview-what-to-look-out-for?cid=CS-ZC-FT-330186 Oct 23, 2018 - Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Loxo Oncology: Out Of The Frying Pan And Into The Fire (Part 2/2) https://seekingalpha.com/article/4200203-loxo-oncology-frying-pan-fire-part-2-2?source=feed_sector_healthcare Aug 17, 2018 -
Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap https://seekingalpha.com/article/4178491-core-biotech-buys-17-positive-commentary-gene-therapy-first-swap?source=feed_tag_etf_portfolio_strategy May 31, 2018 - FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme.A clinical hold for CRISPR Therapeutics caused some concern but I p
Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash https://seekingalpha.com/article/4176837-evelo-biosciences-ipo-undervalued-almost-40-percent-cash?source=feed_tag_ipo_analysis May 24, 2018 - The company has $81.5 million in cash that will be shown in the balance sheet of the next quarterly report.Taking into account the new cash, the company is trading at 2.5x its cash per share.Peers are
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas https://seekingalpha.com/article/4176184-core-biotech-buys-16-taking-advantage-weakness-add-conviction-ideas?source=feed_all_articles May 22, 2018 - Recent weakness in the biotech sector is an opportunity to add to conviction holdings.My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received
Institutional Top Ideas Series: Opaleye Management https://seekingalpha.com/article/4174919-institutional-top-ideas-series-opaleye-management?source=feed_all_articles May 17, 2018 - Opaleye Management is a smaller fund with exceptional performance of late.Their top two holdings are heavily weighted and they are capitalizing on the targeted oncology theme as well.I provide a brief

Pages: 1234567

Page 1>

Related Companies

Name Exchange Price Mkt Cap
ARRY Array BioPharma Inc. NASDAQ $13.73 $2.91B
ASND Ascendis Pharma A/S NASDAQ $68.28 $2.87B
HZNP Horizon Pharma plc NASDAQ $19.22 $3.2B
EBS Emergent Biosolutions, Inc. NYSE $64.89 $3.25B
HRTX Heron Therapeutics, Inc. NASDAQ $33.8 $2.63B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Blueprint Medicines
BPMC - Google Finance https://www.google.com/finance?q=BPMC Industry related info and international coverage Summary News
BPMC - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BPMC Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options